Physician profile
Daniel B Simmons
NPI 1386903359
$728.63
in general payments reported to CMS, 2019-2025
15 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.22 · 2021: $19.92 · 2022: $111 · 2023: $66.34 · 2024: $248 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $126.25 | 2024 | |
| Abbvie INC. | $112.86 | 2024-2025 | |
| Argenx US, INC. | $97.48 | 2022 | |
| Acadia Pharmaceuticals INC | $89.56 | 2024-2025 | Nuplazid |
| Tanabe Pharma America, INC. | $54.74 | 2024 | |
| Lilly USA, LLC | $43.67 | 2022-2025 | Emgality, Reyvow, Kisunla |
| Boston Scientific Corporation | $35.14 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $28.34 | 2023 | Xeomin |
| Cycle Pharmaceuticals INC | $26.13 | 2025 | Bafiertam |
| Eisai INC. | $22.97 | 2025 | |
| Pfizer INC. | $21.54 | 2023 | |
| Celgene Corporation | $18.61 | 2024 | Zeposia |
| Genentech USA, INC. | $18.14 | 2025 | Ocrevus Zunovo |
| Neurelis, INC. | $18.08 | 2025 | Valtoco |
| Janssen Biotech, INC. | $15.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.